Clinical trial
A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
NCT04028245 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial)
- Lead sponsor
- Columbia University
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 15, 2019
- Completion date
- March 5, 2026
- Enrollment
- 17 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.